CBO0 Stock Chart & Stats
€2.44
--
Market closed
€2.44
--
Day’s Range― - ―
52-Week Range€1.38 - €10.76
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€6.94M
Enterprise Value€807.13K
Total Cash (Recent Filing)€4.79M
Total Debt (Recent Filing)€911.75K
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 06, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.86
Shares Outstanding4,202,118
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.67Price Target Upside296.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinically Meaningful Phase II Overall Survival BenefitA ~14.7-month median OS benefit from OVATION II is a durable, program-level efficacy signal that materially de-risks the lead asset. Strong survival data supports regulatory discussions, partner interest, pricing power assumptions and sustained investigator engagement across the Phase III lifecycle.
Pivotal Phase III Progression With Site Enrollment MomentumAn active 500-patient pivotal trial with early enrollment and strong site/investigator engagement lowers operational execution risk. Demonstrated enrollment momentum and engaged sites increase the probability of timely data collection and make the program more attractive to potential partners long-term.
Structured $10M Financing With Limited Immediate DilutionA $10M structured financing that emphasizes non-tradable preferred stock and secured notes extends runway for pivotal enrollment while limiting near-term equity dilution. This financing preserves capital structure flexibility and supports uninterrupted Phase III execution and partner-engagement opportunities.
Bears Say
Near-zero Revenue And Persistent Operating LossesImunon generates virtually no product revenue and runs consistent operating and free cash flow deficits, making it unable to self-fund development. Persistent negative returns on equity and large losses force repeated capital raises and heighten medium-term dilution and execution risk.
Multi-year Timeline To Pivotal Readout And Regulatory ClarityA last-patient estimate in Q1 2029 creates a prolonged path to definitive efficacy and approval. Extended timelines increase exposure to competitive developments, changes in standard of care and cumulative funding needs while delaying any potential commercialization cash flows for years.
Ongoing Reliance On External Capital And Potential DilutionRepeated use of ATM programs, bridge financings and expansion of equity-based incentive capacity signals dependence on markets to fund operations. This structural financing reliance increases the likelihood of future dilution and links execution to volatile capital-market access over the medium term.
Imunon News
CBO0 FAQ
What was Imunon, Inc.’s price range in the past 12 months?
Imunon, Inc. lowest stock price was €1.38 and its highest was €10.76 in the past 12 months.
What is Imunon, Inc.’s market cap?
Imunon, Inc.’s market cap is €6.94M.
When is Imunon, Inc.’s upcoming earnings report date?
Imunon, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Imunon, Inc.’s earnings last quarter?
Currently, no data Available
Is Imunon, Inc. overvalued?
According to Wall Street analysts Imunon, Inc.’s price is currently Undervalued.
Does Imunon, Inc. pay dividends?
Imunon, Inc. does not currently pay dividends.
What is Imunon, Inc.’s EPS estimate?
Imunon, Inc.’s EPS estimate is -0.82.
How many shares outstanding does Imunon, Inc. have?
Imunon, Inc. has 4,202,118 shares outstanding.
What happened to Imunon, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Imunon, Inc.?
Currently, no hedge funds are holding shares in DE:CBO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
CBO0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, potentially transformative clinical data (a ~14.7-month median OS benefit from OVATION II), clear enrollment momentum and favorable safety/translation signals, supported by an active plan to present additional data and to pursue investor-friendly financing. Counterbalancing these positives are a challenging capital market, a materially prolonged Phase III enrollment and readout timeline (last patient expected Q1 2029), and increased near-term cash burn driven by trial start-up costs. Management has outlined a restructuring and creative financing approach to conserve cash and limit dilution, and investor interest appears constructive. Overall, the clinical progress and enrollment momentum materially support upside potential, while financing and timeline risks remain meaningful near-term headwinds.View all DE:CBO0 earnings summariesCBO0 Stock 12 Month Forecast
Average Price Target
€9.67
▲(296.29% Upside)
Technical Analysis
Options Prices
Currently, No data available
---